Opendata, web and dolomites

oWBI

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 oWBI project word cloud

Explore the words cloud of the oWBI project. It provides you a very rough idea of what is the project "oWBI" about.

bearing    2020    drug    nature    convenient    successful    wearable    closer    predictable    companies    flexible    completion    bolus    administration    drugs    intravenous    subcuject    medication    optimal    2015    assist    2025    significantly    larger    synthetic    lower    force    deals    9bn    device    remarkably    market    sc    pharmaceutical    customization    patient    ing    segment    trend    performance    coming    wbi    unlike    86    wbis    prefilled    subcutaneous    97m    75    licensing    mechanical    components    class    injection    paying    dose    dominated    doses    region    business    viscosity    actively    body    eco    injectors    electronic    multiple    worn    company    competitor    paired    with    commercialize    achievement    disease    disposable    cagr    profitability    pressure    self    scj    moving    establishing    grow    migrate    seeking    accumulated    attractive    onto    medical    osmotic    profit    strategy    biologically    170    formulations    combination    ed    depending    aps   

Project "oWBI" data sheet

The following table provides information about the project.

Coordinator
SUBCUJECT APS 

Organization address
address: NORDRE STRANDVEJ 119
city: HELLEBAEK
postcode: 3150
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://subcuject.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUBCUJECT APS DK (HELLEBAEK) coordinator 50˙000.00

Map

 Project objective

With more drugs coming onto the market as combination products, i.e. drug products paired with delivery devices pharmaceutical companies are paying closer attention to integrated delivery systems. Due to: 1) the trend in the change in drug formulations, in order to migrate from intravenous to a more cost-effective and convenient subcutaneous (SC) drug administration; and 2) the trend in moving from synthetic derived drugs to biologically drugs that are more complex and have higher viscosity and therefore require delivery of larger doses; resulted in the need for a new class of injection devices - wearable bolus-injectors (WBIs). WBIs are prefilled, disposable devices that are worn on the body of a patient during the SC self-administration of a large dose of medication. The WBI market is estimated to grow in CAGR of 170% between 2015 – 2020 and achieve €6.9Bn by 2025, and pharmaceutical companies are actively seeking for reliable and cost-effective WBIs, providing optimal injection performance at an attractive unit cost and low cost of customization.

Subcuject ApS (SCJ) is a medical device company set to commercialize a new class of WBIs - Subcuject - that makes use of the simple, predictable and strong force of nature: osmotic pressure. Unlike the current WBIs, Subcuject is fully mechanical, bearing no electronic components, resulting in a more flexible, reliable and eco-friendly device at a remarkably lower cost than competitor’s (75 - 86% cost reduction).

SCJ business strategy is based on establishing multiple licensing deals (depending on the drug type, disease, region) with pharmaceutical companies. The Subcuject device is expected to significantly enhance SCJ’s profitability, with an expected accumulated profit of €97M, 5 years after project completion. Moreover, the successful achievement of the project objectives will assist SCJ to be a leading company in the WBI device segment in a market today dominated by U.S. companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWBI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Starcounter (2017)

In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise Software

Read More  

scanvid (2017)

ScanVid - One-Click Integrated Access to Product-related Digital Content

Read More  

BioAhead (2017)

BioAhead – an innovative optimization algorithm for amino acid chain analytics

Read More